JOHNSON & JOHNSON HIT A $500 BILLION MARKET VALUE AS ITS STOCK EXTENDED A RECORD 13-DAY WINNING STREAK, FUELED BY CONFIDENCE IN NEW DRUGS AND RECENT ACQUISITIONS TO OFFSET STELARA SALES DECLINES. INVESTORS FAVOR DEFENSIVE HEALTH-CARE NAMES, THOUGH ANALYSTS SEE LIMITED UPSIDE FROM CURRENT LEVELS.